A practical reference on PT-141: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-05 and is reviewed periodically as new material appears.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
| Property | Value | Notes |
|---|---|---|
| Storage form | Lyophilized powder | Longer stability at -20 °C |
| Reconstitution solvent | Sterile water or buffer | Depends on intended application |
| Purity assessment | Reverse-phase HPLC | Reported as peak area percentage |
| Identity confirmation | Mass spectrometry | Compared against theoretical mass |
| Main stability concern | Repeated freeze-thaw | May promote aggregation |
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
=== Government efficiency === In 1997, Rolling Stone published a comprehensive snapshot of the US government's implementation of the war on drugs, spanning 44 federal agencies and hundreds of thousands of government workers, and without unified management, oversight, or cohesive strategy. Among the agencies there were over a dozen separate drug intelligence operations. The White House's Office of National Drug Control Policy, home of the drug czar and ostensibly the coordinating agency, had a staff of 150, and a $36 million budget; the overall federal drug war budget for 1998 was $16 billion. Most of the agencies involved did not report to the ONDCP, instead to one of 13 congressional appropriations subcommittees. The largest single share of the budget, $2 billion, went to the Bureau of Prisons. Federal agencies also passed on billions of anti-drug dollars to the states, with little oversight or accountability. In 2024, the ONDCP requested $461 million of a $46 billion federal budget allocated across some 50 federal agencies.
Mass spectrometry is used to separate and measure distinct isotopes present in a sample. Archaeologists typically employ isotope ratio mass spectrometers or IRMSs, consisting of an inlet system, ion source, mass analyser and multiple ion detectors. The sample is usually introduced into the mass spectrometer as a gas, with oxygen and carbon being introduced as carbon dioxide. Strontium is too unstable to be easily handled in gas form, instead, it is evaporated and ionised in a vacuum. This use of a solid source is referred to as thermal ionisation mass spectrometry or TIMS. More recently, strontium isotopes have been at the centre of discussion and investigation into the use of laser ablation inductively coupled mass spectrometry (ICP-MS), which is also of interest due to its less invasive nature. Electron bombardment ionises the gas, allowing the molecules to be focused into a beam which is then split by mass into smaller beams - forming a "mass spectrum". The relative intensities of the different beams is then measured in the ion collector and relayed as isotope ratios.
=== Economics === Tavaborole began phase III clinical trials in December 2010 and was approved by the US FDA in July 2014. Originally developed by Anacor, it is now marketed in the United States by Novartis subsidiary Sandoz. Anacor was paid US$65 million and also entered into a profit sharing scheme for future sales.
Income inequality has traditionally been low in Denmark. According to OECD figures, in 2000 Denmark had the lowest Gini coefficient of all countries. However, inequality has increased during the last decades. According to data from Statistics Denmark, the Gini coefficient for disposable income has increased from 22.1 in 1987 to 29.3 in 2017. The Danish Economic Council found in an analysis from 2016 that the increasing inequality in Denmark is due to several components: Pre-tax labour income is more unequally distributed today than before, capital income, which is generally less equally distributed than labour income, has increased as share of total income, and economic policy is less redistributive today, both because public income transfers play a smaller role today and because the tax system has become less progressive. In international comparisons, Denmark has a relatively equal income distribution. According to the CIA World Factbook, Denmark had the twentieth-lowest Gini coefficient (29.0) of 158 countries in 2016. According to data from Eurostat, Denmark was the EU country with the seventh-lowest Gini coefficient in 2017. Slovakia, Slovenia, Czechia, Finland, Belgium and the Netherlands had a lower Gini coefficient for disposable income than Denmark.
Sources: en.wikipedia.org
== Research == Polymyxins are used to neutralize or absorb LPS contaminants in samples, for example in immunological experiments. Minimization of LPS contamination can be important because LPS can evoke strong reactions from immune cells, distorting experimental results. By increasing permeability of the bacterial membrane system, polymyxin is also used in clinical work to increase the release of secreted toxins, such as Shiga toxin, from Escherichia coli. The global problem of advancing antimicrobial resistance has led to a renewed interest in their use.
== History == Approval by the US Food and Drug Administration (FDA) was based on TRIDENT-1, a global, multicenter, single-arm, open-label, multi-cohort clinical trial (NCT03093116) which included participants with ROS1-positive locally advanced or metastatic non-small cell lung cancer. Efficacy was evaluated in 71 ROS1 tyrosine kinase inhibitor-naïve participants who received up to one prior line of platinum-based chemotherapy and/or immunotherapy and 56 participants who received one prior ROS1 tyrosine kinase inhibitor with no prior platinum-based chemotherapy or immunotherapy. The FDA granted the application for repotrectinib priority review, breakthrough therapy, and fast track designations.
While at the Ohio State, he continued to explore additional applications, including the development of multitarget sRNAs that can be used for metabolic engineering, and the modification of human butyrylcholinesterase for the degradation of the chemical warfare nerve agents in collaboration with the Battelle Memorial Institute. Wood has joint appointments with Department of Chemistry and Biochemistry and the Molecular Biophysics Training Program at the Ohio State University. He is one of a small group of researchers worldwide focusing on intein implementation in various applications, along with Belfort and Tom Muir. Wood's research focuses on developing new technologies by recombining protein domains, particularly in biopharmaceutical development and manufacturing. He has continued refining these methods for biopharmaceutical development and manufacturing, and his work has drawn funding from the DARPA BioMOD project, NIH, NSF and US Army Research Office, projects as well as several industry sponsors. Wood was also involved in the development of protein switches for biotechnology funded by the NSF Career Award. Wood is an author of over 60 publications, six issued patents, two additional patent applications pending and an additional dozen book chapters or edited volumes. His publications have been cited nearly 4000 times. Wood is a member of the American Chemical Society, BIOT division, American Institute of Chemical Engineers, and International Society of Pharmaceutical Engineers.
Sources: en.wikipedia.org
Storage at -20 °C or below is standard for long-term stability. Desiccant and sealed containers limit moisture exposure. Solutions are prepared only when needed.
Reverse-phase HPLC separates components by hydrophobicity and reports purity as a percentage of total peak area. It does not by itself confirm molecular identity. Mass spectrometry is used alongside it for that purpose.
They link a specific lot to its analytical results and storage history. This traceability supports reproducibility when results differ between experiments. Records also help identify when re-testing is warranted.
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.